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Abstract 
 Objectives: To provide recommendations for the selection of comparators for randomized 
controlled trials of health-related behavioral interventions. 
 Study Design and Setting: The National Institutes of Health Office of Behavioral and Social 
Science Research (OBSSR) convened an expert panel to critically review the literature on 
control or comparison groups for behavioral trials and to develop strategies for improving 
comparator choices and for resolving controversies and disagreements about comparators. 
 Results: The panel developed a Pragmatic Model for Comparator Selection in Health-
Related Behavioral Trials. The model indicates that the optimal comparator is the one that best 
serves the primary purpose of the trial, but that the optimal comparator’s limitations and barriers 
to its use must also be taken into account.  
 Conclusion: We developed best practice recommendations for the selection of comparators 
for health-related behavioral trials. Use of the Pragmatic Model for Comparator Selection in 
Health-Related Behavioral Trials can improve the comparator selection process and help to 
resolve disagreements about comparator choices. 
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1. Introduction 
Controversies and disagreements often surround the selection of comparators for randomized 
controlled trials (RCTs) of health-related behavioral interventions. This creates problems for 
investigators, reviewers, and funding agencies; impedes progress in intervention research; and 
diminishes the perceived quality of behavioral RCTs.  
 A scientific priority of the National Institutes of Health Office of Behavioral and Social 
Sciences Research (OBSSR) is to enhance and promote the research infrastructure, methods, and 
measures needed to support a more cumulative and integrative approach to behavioral and social 
sciences research [1]. To advance this scientific priority, OBSSR recently assembled a 
multidisciplinary expert panel on comparator selection in health-related behavioral RCTs. A 
steering committee (WTR, DYH, KEF, ACK) identified candidates for the panel who were 
statisticians, clinical trial investigators or methodologists, or NIH staff who had previously 
published relevant work on RCT methodology or who had responsibilities for research on health-
related behavioral interventions. The final selections were made by the Director of OBSSR 
(WTR); three individuals declined the invitation because of other commitments. 
Following preliminary discussions, the panel convened at the NIH campus in Bethesda 
Maryland on April 12 and 13, 2017. The goals of the meeting were to develop recommendations 
for researchers and reviewers and to produce a report to address key questions about comparator 
choices. The panel considered diverse areas of behavioral intervention research, including 
clinical treatment trials and community-based prevention trials. Disagreements were discussed, 
and votes were taken on the major issues, but the entire panel agreed on all major points. The 
main strength of this process is that it integrated the views of leading experts from diverse fields. 
Its main limitation is that public comments were not obtained. The recommendations reflect the 
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perspective of the expert panel convened by the NIH but does not represent official policy or 
guidance of the NIH. 
This paper presents the consensus view and recommendations of the expert panel.1 It focuses 
primarily on trials in which individuals are the units of randomization, but many of the principles 
also apply to cluster-randomized trials. Its goals are to clarify the reasons why comparators have 
been controversial in health-related behavioral intervention research, and to present the 
Pragmatic Model for Comparator Selection in Health-Related Behavioral Trials (Figure S1) to 
help resolve controversies about comparators and to refine decision-making strategies. The 
recommendations included in this report are intended primarily for researchers who are planning 
or proposing randomized trials of behavioral interventions and for peer reviewers of trial 
proposals and publications, rather than for meta-analysts. 
 
  
                                               
1
 This document presents the full report of the expert panel.  The published manuscript presents a 
summary of this report. Some of the table and figure numbers differ between these two versions. 
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(A) 
Position the trial within an applicable 
framework (purpose, phase, and/or context) 
(B) 
Define primary purpose of the trial 
(primary objective, research question, 
and/or hypothesis) 
(C) 
Choose the optimal comparator 
for the primary purpose of the trial 
(D) 
Significant 
Barriers 
(E) 
Significant 
Limitations 
(F) 
Finalize choice of optimal comparator 
Absent 
Surmountable 
Modify 
comparator 
Insurmountable 
Reconsider 
feasibility 
and purpose 
Absent 
Acknowledge 
limitations, 
ameliorate 
if possible, 
address in 
future studies 
Present 
Figure S1.  The Pragmatic Model for Comparator Selection in Health-Related Behavioral Trials. 
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2. Types and Characteristics of Comparators 
The study arms to which interventions are compared are called “control” groups, arms, or 
conditions in some articles, and “comparison” groups, arms, or conditions in others. The 
distinctions between these terms are neither clear nor consistent. To minimize confusion, we use 
the generic term comparator instead of control or comparison, whenever possible throughout this 
report. Also, when we use the term “trial”, we are referring to an RCT unless otherwise stated. 
 Table S1 lists comparators that are often used in health-related behavioral CTs. A survey of 
behavioral and social science trials found that usual care, no treatment, and active interventions 
were the most frequently-used comparators in protocols published between 2012 and 2016 [2].  
Comparators with the same name may take different forms in different trials. For example, a 
variety of conditions have been called “attention controls” or “attention-placebo control groups.” 
One trial compared a relaxation intervention to a “health enhancement program” [3], while 
another compared a self-regulation intervention to “support and discussion” [4], yet both reports 
referred to the comparators as “attention-placebo” conditions. Some comparators, such as wait 
lists, have been used in trials of many kinds of behavioral interventions. Others have been 
reserved for more specialized applications. For example, pill placebo comparator arms have been 
added to trials in which behavioral interventions were compared to medications [5], but 
behavioral interventions are almost never compared to pill placebos in two-arm trials. 
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Table S1.  Comparators that are often used in health-related behavioral trials. 
 
 
 
Name(s) Description 
Comparators Often Used to Evaluate Whether an Intervention Works at All 
No treatment No intervention is provided.  
Wait list The same intervention that is provided to the experimental group is subsequently 
provided to the comparator group, after the post-test evaluation has been completed. 
 
Comparators Often Used to Determine How Well an Intervention Works Relative to a Clinically Relevant Alternative 
Usual care 
Routine (standard) care 
Treatment as usual 
Treatments or services that are routinely provided in the settings from which trial 
participants are recruited. Often differs across individuals and settings, and in some trials 
may be enhanced or restricted for trial participants. 
Standard of care State-of-the-art, guideline-adherent treatments or services that are routinely provided or 
recommended in the settings from which participants are recruited. In some 
circumstances, the standard of care is provided in a uniform fashion across individuals; in 
others, it may be individually tailored or personalized. 
Optimized care 
Standardized care 
If a “standard of care” exists but it is not being routinely practiced in the setting(s) in 
which the RCT is conducted, usual care may be “optimized” or “standardized” by the 
investigators for the RCT to approximate the current standard of care. 
Alternative intervention Used when one intervention is compared to another intervention for the same problem, 
such as in comparative effectiveness trials. 
Alternative modality A condition that is identical to the experimental intervention except for the modality, 
channel, or source of delivery, e.g., an intervention that is delivered in person instead of 
by videoconference (i.e., a different delivery channel), or an intervention that is delivered 
by a human vs. a computer (i.e., a different intervention source). 
Alternative content A comparator that uses the same technology as the experimental intervention but that 
differs in content or in other details, e.g., a health behavior coaching smartphone app vs. 
a symptom monitoring smartphone app. 
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Name(s) Description 
Supported or unsupported intervention A comparator that uses the same technology as the experimental intervention and that 
provides the same content, but that adds or subtracts additional components, such as a 
human-delivered component (e.g., counselor guidance). 
 
Comparators Often Used to Investigate How or Why an Intervention Works 
Attention control 
Attention-placebo 
Nonspecific therapy  
Umbrella terms for a variety of conditions that are usually designed to provide the same 
amount of contact with the intervention staff or program that will be given to the 
participants in the treatment arm of the trial. May be designed to control for common 
factors of therapy such as support, and/or other ingredients such as educational materials. 
Placebo 
Sham 
A condition that structurally resembles the experimental intervention but that lacks its 
putative active ingredient(s) and that is intended to alter expectancies or to stimulate a 
placebo response. 
Component A condition that is identical to the experimental intervention except lacking one or more 
of its putative active ingredients or elements. 
Dosage A condition that is identical to the experimental intervention except for one or more of its 
dosage parameters, e.g., frequency or duration of contacts. 
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 As shown in Table S2, comparators can be characterized along several dimensions [6], 
including acceptability, feasibility, formidability, relevance, resemblance, stringency, and 
uniformity. The ethical acceptability of a comparator depends on the risks to which the 
participants will be exposed and whether the benefits of the research outweigh these risks. Key 
stakeholders, such as participants, clinicians, or community leaders, may judge the acceptability 
of comparators on other grounds, such as justice, equity, or interference with customary 
practices. For example, an underserved population might reject a proposed RCT in which some 
members of the community would receive free treatment while others would receive no 
treatment, because they would consider that to be unjust. As another example, physicians might 
be unwilling to participate in an RCT if they were concerned that random assignment of their 
patients to the comparator arm would interfere in some way with their clinical care. 
 
Table S2. Key characteristics of comparators used in health-related behavioral trials. 
 
Characteristic Definition 
Acceptability Whether the comparator meets current standards for the ethical conduct of 
research and satisfies stakeholder requirements. 
Feasibility Whether the comparator can be successfully implemented, given the trial’s 
resources and environment. 
Formidability How much pre-post change the comparator induces (or is expected to induce) in the outcome. 
Relevance How closely the comparator corresponds to “real world” interventions, 
services, or programs. 
Resemblance How similar the comparator is to the intervention to which it is being 
compared. 
Stringency How well the comparator controls for threats to internal validity and helps to 
minimize biases. 
Uniformity How homogeneous the comparator is across participants or sites. 
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 The feasibility of a comparator pertains to the practicability of implementing it. This 
depends, to a large extent, on the resources available for the trial and the environment in which it 
will be conducted. For example, a small research grant might provide sufficient funds to compare 
an intervention to no treatment, but not enough to compare it to an alternative intervention.  
Formidability refers to the magnitude of pre-post change that the comparator induces (or that 
it is expected to induce). The more (beneficial) change the comparator induces, the more difficult 
it is for an intervention to outperform it in a superiority trial or to approximate its performance in 
a noninferiority trial [7]. For example, a well-established, evidence-based intervention would be 
a more formidable comparator for a novel intervention than a wait list would be. 
Relevance is the extent to which the comparator corresponds to real-world interventions, 
services, or programs. For example, an evidence-based intervention that is used routinely to treat 
a certain condition would be a clinically relevant comparator for novel interventions for that 
condition. In contrast, a “psychoeducation program” that is designed de novo as an attention-
placebo comparator for an RCT but that is never provided as part of routine patient care or 
community-based services would have low clinical or public health relevance.  
The resemblance of the comparator refers to the extent to which it resembles the 
intervention. Trials in which the comparator strongly resembles the intervention provide some of 
the only examples of double-blinding in health-related behavioral intervention research. For 
example, sham biofeedback equipment and procedures are so similar to genuine biofeedback, 
except for the verity of the feedback, that most trial participants cannot tell which group they are 
in. In contrast, the participants in an “aerobic exercise vs. cognitive therapy” trial could easily 
tell which group they are in because the interventions do not resemble one another. 
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Stringency refers to how well threats to internal validity and other biases are controlled. 
Stringent comparators are ones that help to minimize or eliminate these problems. A stringently 
controlled trial is one in which the outcomes can be attributed with reasonable certainty to the 
effects of the intervention rather than to biases, confounds, or other rival explanations.  
Finally, uniformity refers to the homogeneity or heterogeneity of the comparator across trial 
participants or sites. For example, everyone in the comparator arm of a standard drug trial 
receives identical pill placebos; in contrast, the content of a nonstandardized “supportive 
counseling” condition may differ considerably across sites, counselors, and participants.  
 
 3. Sources of Controversy 
The panel identified several reasons why comparators have been controversial in health-
related behavioral intervention trials. First, comparator choices can have profound effects on the 
purpose, feasibility, fundability, results, and impact of RCTs. Disagreements about comparators 
are not simply methodological disputes; they have broader ramifications for intervention 
research [8]. In many cases, disagreements about comparator choices are proxies for 
disagreements about the primary purpose of the trial. Such disagreements are often resolved by 
replacing the planned comparator with a different one. Unfortunately, the result may be a trial 
that cannot answer the original research question, or one whose de facto primary purpose is not 
the one that the investigator had intended to pursue. 
Second, the attributes discussed above are often in tension with one another. There are 
situations, for example, in which it might be desirable to have a usual care comparator that is 
both clinically relevant and very uniform. However, this combination may be unattainable 
because usual care tends to be clinically relevant but heterogeneous. In contrast, artificial 
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comparators that are designed de novo to balance nonspecific treatment effects or parameters 
between groups may be homogeneous but clinically irrelevant. When it is impossible to find or 
design comparators with an ideal combination of attributes, one is left to choose among 
imperfect alternatives. Consequently, disagreements about comparator choices often reflect 
differences of opinion about unavoidable tradeoffs among comparator attributes. 
 Third, many trials have compared health-related behavioral interventions to no-treatment or 
wait-list conditions. These trials have been criticized as merely showing that behavioral 
interventions are better than nothing [9]. They have also been contrasted with double-blind, 
placebo-controlled drug trials, and judged to be less stringent. This has led some researchers to 
conclude that health-related behavioral trials should always control for attention or placebo 
effects and that comparators should always be standardized (i.e., uniform). Others disagree with 
this solution and argue that it is likely to create more problems than it prevents. 
This debate reflects a misguided tendency to equate the stringency and formidability of the 
comparator with the overall scientific rigor of an RCT. NIH defines scientific rigor as the strict 
application of the scientific method to ensure robust and unbiased experimental design, 
methodology, analysis, interpretation and reporting of results [10]. By extension, RCTs are 
rigorous to the extent that they produce trustworthy, informative, and replicable findings. This 
requires tighter control over explanatory variables in some trials than in others, and more 
formidable comparators in some trials than in others.  
 Many of the earliest psychotherapy and behavioral intervention studies were stringently-
controlled laboratory experiments. They had the advantage of tight experimental control and 
high internal validity but were criticized for lacking generalizability to clinical or community-
based interventions [11]. Most of these studies randomly assigned participants to conditions that 
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were identical except for one specific difference, to isolate the effect of the independent variable 
on the dependent variable. For example, a trial of desensitization of spider phobia compared 
massed vs. spaced exposure; there were no other differences between the conditions [12].  
 In contrast, contemporary health-related behavioral intervention research emphasizes 
generalizability and utility. This has led to a shift toward comparisons between conditions that 
differ in multiple ways rather than in single, discrete characteristics. RCTs that are conducted in 
clinical or community settings and that compare complex behavioral interventions to usual care 
exemplify these trends [13]. These are adaptive responses to growing societal needs for clinically 
useful research [14], but they clash with the traditional experimental paradigm of discrete and 
tightly-controlled independent variables.  
 
4. Existing Approaches to Comparator Selection 
4.1 Background 
The panel reviewed the scientific literature on comparators as well as select research 
methodology textbooks [15-20] and other methodology training materials to identify existing 
guidance frameworks and informative perspectives. The search yielded a variety of 
recommendations based on study purpose, research phase, research ethics, research context, 
empirical evidence, trial quality, and cumulative science.  
Table S3 lists a variety of translational research frameworks that help to clarify how the 
purposes, phases, and contexts of health-related intervention research affect comparator choices. 
An underlying premise of these frameworks is that intervention research progresses (often in a 
nonlinear or recursive fashion) from basic science to intervention development and refinement, 
to efficacy tests, to more pragmatic trials, and ultimately to implementation research. This occurs 
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along a dimension of intervention maturity. Figure S2 shows how the frameworks map onto 
different regions of the intervention maturity dimension.  
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Table S3. Translational research frameworks. 
 
 
Title Brief Summary 
International Conference on Harmonization [21]  
 
Classifies drug studies by their objectives: human pharmacology, therapeutic 
exploratory, therapeutic confirmatory, therapeutic use. Developed primarily for 
pharmaceutical research, but much of it is applicable to health-related behavioral 
trials. Correlates the major objectives of trials with the traditional phases of drug 
development (Phases I, II, III, and IV). Adopted by the FDA [22]. 
Institute of Medicine’s Operational Phases of 
Translational Research [23] 
Arrays phases of health-related research along a continuum that ranges from basic 
science (T0), translation to humans (T1), translation to patients (T2), translation to 
practice (T3), and translation to community (T4). 
Stakeholder-Informed Framework [24] 
Argues that the risks to stakeholders of erroneous findings shift between early and 
late phases of research. The dominant early-phase threats are Type II errors that can 
stifle research on innovative interventions. The threats in later phases are Type I 
errors and clinical implementation of ineffective treatments. 
Phase Framework for Behavioral Interventions 
[25, 26] 
Suggests that comparators are often irrelevant in both the earliest and the latest 
phases of research. Stresses comparisons of different dosages of new interventions in 
Phase II and of new vs. established interventions in Phase III. 
Obesity Related Behavioral Intervention Trials 
(ORBIT) model [49] 
Provides an iterative framework for intervention development and testing. Starts with 
identification of a significant clinical question that may require multiple studies to 
address. Development and testing the intervention progresses from Phase I (design) 
through II (preliminary testing), III (efficacy), and IV (effectiveness). Allows returns 
to earlier phases for further development and testing when needed. 
NIH Stage Model for Behavioral Intervention 
Development [27] 
Spans Stage 0 (basic research), I (intervention generation/refinement), II (efficacy in 
research clinics), III (efficacy in community clinics or other relevant settings), IV 
(effectiveness), and V (implementation and dissemination). Encourages examination 
of mechanisms of behavior change at every stage of intervention development, as 
well as careful consideration of the intervention’s implementation potential. 
Multiphase Optimization Strategy (MOST) [51] 
Emphasizes identification of the most efficient and effective combination of 
intervention components prior to testing of the intervention in an RCT. Components 
are initially evaluated in the screening phase, investigated in greater detail in the 
refining phase, and tested as a complete intervention in the confirming phase. 
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Title Brief Summary 
Purpose-Guided Trial Design (PGTD) [6] Identifies four types of behavioral trials with different primary purposes. Links the dominant purpose of the comparator to the primary purpose of the trial. 
Pragmatic Explanatory Continuum Indicator 
Summary (PRECIS-2) [52] 
Describes a continuum from very explanatory to very pragmatic trials. Explanatory 
trials are conducted in ideal settings to give interventions the best chance of showing 
beneficial effects. Pragmatic trials are conducted in real world settings to inform 
decisions about whether to use interventions in practice. 
Medical Research Council Framework for the 
Development and Evaluation of RCTs for 
Complex Interventions to Improve Health [53] 
Includes four stages. 1) Development: complex intervention processes and outcomes 
are derived from existing evidence. 2) Feasibility and Piloting: recruitment, retention, 
and other procedures are tested and sample size requirements are determined. 3) 
Evaluation: effectiveness and cost-effectiveness are assessed and change processes 
are characterized. 4) Implementation: intervention is disseminated, surveillance and 
monitoring systems are established, and long-term follow-up studies are conducted.  
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# Framework 
Intervention Maturity 
Low ↔ Intermediate ↔ High 
1 International Conference on Harmonization (ICH) / Food and Drug Administration (FDA) 
Human 
Pharmacology 
Therapeutic 
Exploratory 
Therapeutic 
Confirmatory 
Therapeutic 
Use 
2 Institute of Medicine (IOM) Phases of Translational Research T0 Basic Science 
T1 
Translation to 
Humans 
T2 
Translation to 
Patients 
T3 
Translation to 
Practice 
T4 
Translation to 
Community 
3 Stakeholder-Informed Framework  
Phase I 
Development 
and Feasibility 
Phase II 
Preliminary 
Testing 
Phase III 
Large Multicenter 
Efficacy Trials 
Phase IV 
Effectiveness 
Trials 
4 Phase Framework for Behavioral Interventions  Phase I Feasibility 
Phase II 
Dose-Response 
Phase III 
Efficacy 
Phase IV 
Effectiveness 
Phases V-VII 
Implementation 
5 Obesity-Related Behavioral Intervention Trials (ORBIT) Model  Phase I Design 
Phase II 
Preliminary 
Testing 
Phase III 
Efficacy 
Phase IV 
Effectiveness 
6 National Institutes of Health (NIH) Stage Model 
Stage 0 
Basic 
Research 
Stage I 
Intervention 
Generation & 
Refinement 
Stage II 
Efficacy in 
Research Clinics 
Stage III 
Efficacy in 
Community 
Clinics 
Stage IV 
Effectiveness 
Stage V 
Implementation 
& Dissemination 
7 Multiphase Optimization Strategy (MOST)  
Intervention 
Component 
Screening 
Phase 
Intervention 
Refinement 
Phase 
Confirmatory 
Phase  
8 Purpose-Guided Trial Design (PGTD) framework  Intervention-Oriented Trials 
Outcome-Oriented 
Trials 
Utility-Oriented 
and 
Experimental 
Trials 
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# Framework 
Intervention Maturity 
Low ↔ Intermediate ↔ High 
9 Pragmatic Explanatory Continuum Indicator Summary  (PRECIS-2)  
Very 
Explanatory 
Trials 
Rather 
Explanatory 
Trials 
Rather 
Pragmatic 
Trials 
Very 
Pragmatic 
Trials 
 
10 MRC Framework for the Development and Evaluation of RCTs for Complex Interventions Development 
Feasibility/ 
Piloting Evaluation Implementation 
 
Fig S2.  The intervention maturity dimension in translational research frameworks. The alignment of frameworks in this figure 
is a rough approximation; it is not intended to be interpreted as an exact map. 
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4.2 Study purpose 
A consistent theme in the literature on RCT methodology is that trials should be designed to 
serve the study’s primary purpose (i.e., its main aim, objective, hypothesis, or research 
question). This principle is implicit in many discussions of comparators, but it plays an 
especially prominent role in three methodological frameworks. First, the International 
Conference on Harmonisation [21, 28] and the U.S. Food and Drug Administration [22, 29] 
assert that the choice of the comparator for an RCT should be based on the objective of the trial. 
Their recommendations stress the importance of choosing comparators that are “adequate to the 
task,” and they do not assume that that certain comparators are either inherently inadequate or 
inherently useful for every type of trial and every therapeutic research objective.  
Second, Purpose-Guided Trial Design (PGTD) [7] is a heuristic framework for behavioral 
trial design. Its fundamental principle is that the design of a behavioral trial should fit its primary 
purpose. It posits that the primary purpose of the trial outweighs all other considerations. If the 
comparator that best fits the purpose of the trial cannot be used (e.g., due to ethical constraints), 
the PGTD framework argues that it should not be replaced by an alternative comparator that does 
not serve the primary purpose of the trial, because doing so would leave the primary research 
question unanswered. Unless there is a suitable alternative, the investigator should reconsider 
whether it is feasible under the circumstances to answer the primary research question.  
Third, the Obesity-Related Behavioral Intervention Trials (ORBIT) model provides a 
systematic framework for developing and testing behavioral interventions for preventing and 
treating chronic diseases [30]. The model includes four phases (Phases I-IV). The primary 
purposes of intervention studies differ across these phases, but all of them are designed to answer  
a “significant clinical question” as their overriding, long-term purpose. 
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4.3 Research phase 
Schwartz et al. [26] described four phases of behavioral intervention research. Phase I studies 
are for the development and testing of interventions. They are usually not RCTs, and they do not 
require the kind of comparators that are discussed in this report. Phase II studies compare 
different dosages of the same intervention. Phase III efficacy trials compare new interventions to 
existing ones. Phase IV studies use case-control designs to confirm effectiveness in “real-world” 
settings. Later phases include practice-based implementation studies (Phase V), widespread 
diffusion (Phase VI), and institutional- and policy-level interventions (Phase VII). Of these three, 
only Phase V studies typically require comparators [25]. This framework shows that different 
comparators are needed in different phases of behavioral intervention research. 
Mohr et al. [24] noted that stakeholder interests shift across the phases of intervention 
research, and that this affects comparator choices. When a novel intervention is developed or an 
existing intervention is revamped or repurposed, stakeholder interests are best served in the early 
phases of research by giving the intervention a chance to demonstrate its potential value. The use 
of excessively formidable comparators in Phase I studies and in initial Phase II trials can 
decrease the chances of finding a signal, quash further work on promising interventions, and 
thereby deprive stakeholders of potential benefits. In contrast, later Phase II and Phase III 
efficacy trials are designed to inform decision-making by service providers and policy-makers. 
Type I errors, i.e., conclusions that interventions have benefits when in fact they do not, pose a 
greater risk to stakeholders in late-phase research. The use of comparators that are not very 
formidable  in advanced Phase II and Phase III trials of behavioral interventions, including ones 
that have passed low-formidability tests in earlier studies, can increase the risk that ineffective 
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interventions will be adopted. Thus, comparators with different degrees of formidability may be 
needed at different phases of research on an intervention, because stakeholder interests shift. 
This means that intervention developers should plan ahead during their early-phase work for 
the higher-formidability tests that will be conducted in later phases. An intervention may have to 
be refined and strengthened if early, low-formidability tests have shown promising results, to 
improve the chances that it will be able to withstand subsequent, higher-formidability trials. 
 The fractional factorial optimization trials that may be conducted as part of the multiphase 
optimization strategy (MOST) are based on a different logic of experimental control than an 
RCT, and they typically do not require traditional comparators [31, 32]. These trials examine the 
components of a complex intervention, rather than the intervention as a whole. Consequently, a 
comparator for the intervention as a whole, such as a placebo condition, may be unnecessary 
[31]. Similarly, in the Design phase (Phase I) of the Obesity-Related Behavioral Intervention 
Trials (ORBIT) framework for developing behavioral interventions [30], small-N or single-case 
designs examine the intervention’s components, dosage parameters, targets, and modes of 
delivery without between-group comparators. In the Proof-of-Concept phase (Phase IIa), quasi-
experimental, within-subject designs evaluate the intervention’s ability to produce a clinically 
significant improvement on the behavioral target. Comparators are not essential in these studies. 
Thus, the phase of research affects not only choices among comparators, but also whether a 
comparator is needed at all. 
 
4.3 Research ethics 
The ethics of placebo- and sham-controlled trials have been vigorously debated [33-38]. 
Ethical issues also have been raised about other comparators used in behavioral RCTs [39]. 
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Against this backdrop, a comparator choice that seems reasonable to an investigator may 
nevertheless be questioned by an institutional review board (IRB). Discussions of the potential 
risks and harms associated with various comparators, and recommendations for addressing 
ethical concerns about comparators, may be found in textbooks on the responsible conduct of 
research [40] and in journal articles on clinical research ethics [e.g., 34, 41, 42]. Key 
considerations include inequity of care, inadequate transparency (e.g., deception), risks from 
exposure to the comparator condition, and opportunity costs, especially if participants in the 
comparator arm are discouraged from seeking nonstudy care for the target of the intervention.   
  
4.5 Research context 
Contextual factors such as current standards of practice, the setting in which a trial is 
conducted, or the characteristics of the population, can affect the feasibility, acceptability, and 
stringency of comparators [43, 44]. For example, resistance to the use of certain comparators 
(e.g., no treatment) is common in community-based participatory research (CBPR) [45]. As 
another example, some comparators are infeasible in certain clinical research settings; e.g., it 
may be impossible to ensure that a “no treatment” group will indeed receive no treatment when 
interventions are available to participants through health care providers who are not involved in 
the trial [6]. Social context effects also play important roles in cluster randomized trials [46].  
 
4.6 Empirical evidence 
The growing empirical literature on comparators is challenging some long-held assumptions. 
For instance, it is often assumed that no-treatment, wait-list, and placebo comparators are 
interchangeable in terms of their formidability. However, recent network meta-analyses of 
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interventions for depression [47] and social anxiety disorder [48] found greater improvement in 
participants who were assigned to no-treatment or placebo than in those who were assigned to 
wait-list comparators. Thus, these conditions differ with respect to their formidability. This 
illustrates the value of empirical research to inform comparator choices. 
 
4.7 Trial quality  
Meta-analysts and clinical guideline panels often use instruments such as the Cochrane Risk 
of Bias tool [49] or the Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE) system [50] to rate their confidence in the evidence. If a trial’s methodological rating 
could be improved by choosing one kind of comparator rather than another, it would be 
advantageous to take this into account. GRADE, for example, downgrades the evidence rating 
for “indirectness” if two interventions of interest have not been tested in head-to-head trials and 
their relative efficacy can only be judged in relation to other comparators [51]. For the most part, 
however, these rating scales do not reward certain comparator choices or penalize others. Thus, 
they provide few clues as to which comparators to choose for RCTs of behavioral interventions. 
 
4.8 Cumulative science 
High-quality meta-analyses of RCTs are among the best sources of evidence to guide clinical 
and public health policies and practices [52, 53]. Network meta-analyses can make indirect 
comparisons between conditions that have not been directly pitted against one another in RCTs. 
However, indirect meta-analytic comparisons are more vulnerable to selection biases than are 
meta-analyses of conditions that have been directly compared to one another in RCTs  [54].   
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Direct, pairwise meta-analytic comparisons are possible only if enough RCTs of an 
intervention employ the same comparator. If comparator choices were dictated by this 
consideration, researchers would be obliged to employ whichever comparator had been used in 
previous trials of the same intervention. However, they have a higher responsibility to ensure that 
their own trial is optimally designed to answer the research question that it is intended to answer, 
even if that means using a different comparator than has been used in previous trials. Whether 
the trial will meet the inclusion criteria for future meta-analyses is a less important concern for 
clinical trialists.  
Comparative effectiveness research (CER) and comparative efficacy trials have raised some 
additional questions about the cumulative science of intervention research. One way to compare 
two interventions is to conduct a randomized, head-to-head trial. Another way is to conduct 
separate trials in which each intervention is tested against the same kind of comparator (e.g., a 
placebo control condition), and then to aggregate the findings in a meta-analysis. Although 
network meta-analyses can be very informative, they are more vulnerable than are direct, head-
to-head trials to biases due to differences in the samples, interventions, comparators, and other 
factors. All else being equal, direct comparisons receive higher GRADE “quality of evidence” 
scores than indirect comparisons [55].   
However, there are also some problems with head-to-head comparisons. One is that relatively 
new interventions rarely yield dramatically better outcomes than well-established, evidence-
based interventions. Consequently, trials that test whether a newer intervention is superior to an 
established intervention usually have to be powered to detect relatively small differences 
between the interventions, so they require large samples [56]. Another is that it is not uncommon 
for the sponsor or the investigator(s) to have a vested interest in one of the interventions but not 
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in the other, a situation that can lead to biased outcomes. This has been problematic in industry-
sponsored pharmaceutical research [57, 58], but it can also affect behavioral intervention 
research when the investigators have an allegiance to a particular intervention [59]. 
 
5. General Principles of Comparator Selection 
5.1 Optimal comparator for the research question 
Based on its critical review of the literature on comparators, the panel unanimously agreed 
that compatibility with the primary purpose of the trial is the single most important consideration 
in choosing a comparator. The optimal comparator is the one that will provide the clearest 
answer to the primary research question or the strongest test of the trial’s primary hypothesis. 
The rationale for the choice of the comparator should start with the primary purpose of the trial, 
and it should not be premised on less important considerations or on arbitrary rules. 
However, there may be barriers to the use of the optimal comparator in some circumstances. 
Also, the comparator that best fits the trial’s primary purpose may leave other questions 
unanswered or impose other limitations on the study. If the comparator’s optimality for the 
primary purpose of the trial would be diminished by addressing these questions or limitations, it 
may be better to address them in subsequent trials instead. Thus, it is necessary to consider not 
only the trial’s primary purpose but also barriers and limitations when choosing a comparator. 
Investigators should clearly explain their choice of comparator, disclose any alternatives that 
were considered, explain why they were rejected, and acknowledge any salient limitations 
related to the comparator. Reviewers who are called upon to evaluate research, should, in turn, 
judge comparator choices first and foremost in relation to the trial’s primary purpose, hypothesis, 
or research question, while recognizing the limitations such decisions often incur. They should 
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also be wary of requesting changes in comparators that would change the primary purpose of a 
proposed trial. 
For example, the primary purpose of a randomized comparative effectiveness trial is to 
compare two interventions to one another, not to evaluate the effects that either one might have 
relative to no intervention [60]. Consequently, a no-treatment comparator arm would be 
superfluous in this type of trial. The absence of a no-treatment arm might leave some potentially 
interesting questions unanswered, but it would not prevent the trial from achieving its main aims. 
 
5.2 Barriers 
If there is an insurmountable barrier to the use of the comparator that best fits the purpose of 
the trial, the investigator should consider whether it can be modified to overcome the barrier 
without sacrificing its goodness-of-fit. If that is not possible (e.g., if it would be unethical to 
randomize participants to a no-treatment arm that would deprive them of essential care), the 
investigator should determine whether a different comparator could overcome the barrier while 
still fitting the primary purpose. If one cannot be identified, then it may not be feasible to 
conduct the trial in a way that would answer the primary research question or test the primary 
hypothesis. Faced with this dilemma, the investigator should reconsider the purpose and design 
of the study, and decide whether a different question, hypothesis, or design should be pursued 
instead. 
 It may be possible to conduct an informative test of the primary hypothesis or to answer the 
primary research question if minor modifications of the optimal comparator would suffice, but 
not if a major modification or a replacement comparator is required. In this circumstance, it 
might be better to consider pursuing other objectives instead. Also, when ethics board members, 
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grant reviewers, and others who are charged with evaluating trial designs ask for substantial 
modification or replacement of an optimal comparator, they should consider whether this will 
prevent the investigator from testing the primary hypothesis or answering the primary research 
question. Of course, it is to the investigator’s advantage to try to anticipate and address any 
ethical issues or other concerns that might be raised about the comparator, before submitting a 
proposal to conduct an RCT of a health-related behavioral intervention.  
 
5.3 Limitations 
A comparator may be the best choice for testing a trial’s primary hypothesis or answering its 
primary research question yet be less than ideal in other respects. It may leave some secondary or 
exploratory questions unanswered or create opportunities for certain biases to affect the trial. 
Unlike ethical or resource constraints or vigorous stakeholder objections, such limitations do not 
create absolute barriers to the use of the comparator of choice. They may, however, affect the 
validity or utility of some of the conclusions that may be drawn from the results.  
Thus, the justification for the choice of a comparator should address any important and 
foreseeable limitations and clarify any methodological compromises that may have to be made in 
order to answer the primary research question or test the primary hypothesis. It should also 
consider whether the comparator can be modified to minimize its limitations without affecting its 
compatibility with the primary purpose of the trial, and whether an alternative comparator might 
be equally compatible but with fewer or less severe limitations. If significant limitations remain 
after modifications and alternatives have been explored, their implications should be discussed.  
As a hypothetical example, assume that there is an established intervention (A), and a newer 
one (B). The best way to determine whether B is superior to A would be a direct, head-to-head 
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comparison in an RCT. However, A is a 6-session intervention and B is a 10-session 
intervention. Thus, the active ingredients of the interventions will not be the only difference 
between the arms of the trial; the amount of contact will also differ.  
The choice of A as the comparator for B might be criticized because the type of intervention 
would be “confounded” with the amount of contact. This would not be a valid criticism, because 
the amount of contact is an integral feature of each intervention, not a confounder. Nevertheless, 
if B turns out to be superior to A, critics could argue that A might have produced better results if 
it were four sessions longer. The fact that this question was left unanswered could be considered 
a limitation of the trial. When the trial was being designed, it might have been possible to 
artificially lengthen A (or artificially shorten B), to equalize the amount of contact. This strategy 
was employed, for example, in a trial comparing psychodynamic therapy to CBT for social 
anxiety disorder [61]. Unfortunately, this approach leaves the primary research question 
unanswered; the results are uninformative as to whether unaltered B, which reflects how B is 
delivered in real-world circumstances, is superior to unaltered A. If the dosages of these 
interventions had been evaluated and optimized before they were compared to each other in a 
head-to-head RCT, it would be easier to justify the differential-dosage design. Regardless, 
having to justify this design would be a small price to pay for preserving the real-world relevance 
of both arms of the RCT.  
 
6. The Pragmatic Model for Comparator Selection 
The Pragmatic Model for Comparator Selection in Health-Related Behavioral Trials (Figure 
S1) is a new approach developed by the expert panel. Its core principle is that the optimal 
comparator is the one that best serves the primary purpose of the trial. If a comparator is chosen 
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on any other basis, it may not fit the trial’s primary purpose. This can happen, for example, if a 
barrier to the use of the optimal comparator is encountered and as a result, it is replaced with one 
that is feasible to use but that does not serve the primary purpose of the trial. It can also happen if 
the optimal comparator’s limitations are given greater weight than its compatibility with the 
trial’s primary purpose, and as a result, a suboptimal comparator is chosen instead.  
These problems can be prevented by following the model’s decision-making algorithm, in 
which the comparator that best serves the primary purpose of the trial is identified before barriers 
and limitations are addressed. It may be possible to overcome some barriers through minor 
modifications of the optimal comparator. Others may be insurmountable, and this may compel 
the investigator to revisit the feasibility or purpose of the trial. The limitations of the comparator 
are considered only after it has been determined that there are no insurmountable barriers to its 
use and any surmountable barriers have been resolved. The limitations are acknowledged, 
ameliorated if possible, and/or addressed in future studies if it would be both feasible and 
informative to do so. The output of the algorithm is the comparator that best fits the primary 
purpose of the trial, despite its limitations. 
 The Pragmatic Model for Comparator Selection encourages researchers to choose clinically 
relevant  rather than artificial comparators that are unlikely to ever be used in practice, unless the 
primary purpose of the study requires an artificial comparator to isolate a mechanism of change 
or a specific component of the intervention. It acknowledges that tradeoffs among comparator 
attributes can create unavoidable methodological limitations, and asserts that tolerable 
limitations should not be allowed to stand in the way of informative research. On the other hand, 
resource constraints and unacceptable risks to participants or to other stakeholders can pose 
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legitimate barriers to the use of otherwise optimal comparators. The algorithm includes a path for 
researchers who encounter such barriers and who must therefore seek alternatives. 
 
7. Selected Applications of the Model 
7.1 Introduction 
The Pragmatic Model for Comparator Selection provides a general strategy for the selection 
of optimal comparators. This section discusses the application of the model to some specific 
challenges in behavioral RCT design. It follows the same sequence as the algorithm. 
 
7.2 Positioning and justifying the study within an applicable research framework 
The translational research frameworks listed in Table S3 and Figure S2 suggest that 
advances in intervention research typically emerge from phased research programs, including 
ones that span multiple research teams, rather than from isolated studies. By positioning and 
justifying their trial within an applicable research framework and by reviewing relevant studies 
and meta-analyses, investigators can show what led up to their trial and what is likely to follow. 
This helps to clarify the purpose of the trial and explicate the reasons why a certain comparator 
should be used and why others should not. 
For example, a proposal to conduct an uncontrolled trial might be rejected on the grounds 
that such studies are inherently uninformative. They are indeed uninformative with respect to the 
efficacy or effectiveness of mature interventions (e.g., Stages II-IV in the NIH Stage Model or 
Phases II-IV in the ORBIT Model), but they can be very useful in Stage I (intervention 
development and refinement) or Phases I and II (intervention design and preliminary testing). 
Positioning and justifying an early-phase study within the MOST framework, the NIH Stage 
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model, the ORBIT model, or other applicable framework can help the investigator define its 
primary purpose and explain why other research questions or hypotheses (such as ones that 
would be more appropriate for a later phase of research) will be deferred to later trials. 
As another example, pragmatic trials are typically conducted on relatively mature 
interventions. Because they are intended to test them under real-world conditions, usual care or 
treatments that are routinely provided in clinical or community practice settings are typically the 
most appropriate comparators in these trials [62]. The heterogeneity of usual care makes it 
unsuitable for RCTs in which stringent and uniform control over explanatory variables is critical, 
but it is consistent with the primary purpose of pragmatic trials that test the effectiveness of 
interventions against the heterogeneous care that participants would ordinarily receive in real-
world practice. The PRECIS-2 tool [62] can be used to position a proposed pragmatic trial along 
the explanatory-pragmatic continuum, and thereby help to build a case for choosing an 
appropriately realistic comparator and for defending its methodological limitations. 
 
7.3 Defining the primary purpose of the trial  
This step in the algorithm moves from the generic objectives of the translational research 
frameworks discussed above to a specific aim, research question, or hypothesis. For example, a 
research team that has been developing and refining a novel intervention might decide, based on 
the ORBIT model, that their next study should be a Phase III efficacy trial. Their next task is to 
define the specific aims of this trial. 
 The Population, Intervention, Comparator, Outcome, and Timing (PICOT) format is helpful 
for framing clear research questions [63, 64]. It bridges the gap between the generic questions 
that emerge from translational research models and the specific ones that investigators have 
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about interventions and outcomes. PICOT makes close connections between research questions 
and comparators, particularly in RCTs of relatively mature interventions. It also acknowledges 
that RCTs estimate the relative efficacy or effectiveness of interventions, and that they do so in 
comparison to specific comparators and within particular contexts. The PICOT format thereby 
helps to counteract the erroneous assumption that the purpose of an RCT is to determine the 
absolute, comparator-independent and context-free efficacy or effectiveness of an intervention. 
 
7.4 Choosing the optimal comparator 
Once the trial’s aims have been specified and justified, the next step is to choose the optimal 
comparator, if a comparator is needed. In some cases, several different comparators may be 
potential candidates. In other cases, the primary purpose or hypothesis may be tightly coupled 
with a particular comparator. For example, at least 15 RCTs have tested the hypothesized 
contribution of the eye movement component of Eye Movement Desensitization and 
Reprocessing (EMDR) to therapeutic outcomes [65]. All of these trials have compared EMDR 
with versus without eye movements; no other comparator would have fit their primary purpose. 
 As another example, the comparator in a noninferiority trial must be an active intervention 
that represents the current standard of care for the problem or disorder of interest [66]. When 
there is more than one well-established, evidence-based intervention, the investigator can select 
the one that is best suited to the study’s goals and resources. However, if only one intervention is 
generally considered to be the standard of care, it is the only comparator that should be used to 
evaluate the noninferiority of a novel intervention. 
Some research funding opportunities also stipulate comparators that are either acceptable or 
unacceptable. For example, the methodology standards for Patient-Centered Outcomes Research 
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Institute (PCORI) proposals state that, “generally, usual care or nonuse comparator groups 
should be avoided unless these represent legitimate and coherent clinical options” [67].   
Many research questions that can be asked about health-related behavioral interventions 
pertain to whether the intervention works at all, how well it works relative to clinically relevant 
alternatives, or how or why it works. A comparator that is optimal for addressing one of these 
questions is unlikely to be optimal for addressing any of the others. 
Whether the intervention works at all: Very low formidability comparators such as wait lists 
and no-treatment conditions are useful in early-phase trials in which the primary research 
question focuses on whether the intervention has any effect at all. These comparators control for 
changes in the outcome variable(s) that may occur without intervention (e.g., due to spontaneous 
recovery or regression to the mean). Consequently, between-group differences reveal whether 
the intervention has any effects that cannot be explained by the natural history of the target 
problem. This question cannot be answered if the comparator includes an intervention of some 
sort, even if it is a relatively weak intervention.  
How well the intervention works relative to a clinically relevant alternative: Relevance is a 
key attribute of comparators in trials that are designed to determine whether an intervention 
produces better outcomes than a clinically relevant alternative produces. The reason is that this 
research question is only worth asking if the comparator is a genuine alternative. The most 
relevant alternatives tend to be services, interventions, or programs that are already established 
and available to the population of interest. Relevant comparators include a) ones that reflect 
existing clinical or public health practices or services (e.g., usual care or standard of care), b) 
alternative interventions (e.g., a well-established, evidence-based intervention as a comparator 
for a newer intervention), and c) clinically-relevant variations on the experimental intervention 
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(e.g., the same intervention except delivered via an alternative modality, such as when a face-to-
face intervention is compared to the same intervention delivered via remote telehealth 
technology). 
 If multiple relevant alternatives exist, refinement of the hypothesis or research question can 
help to narrow the range of options. Also, some of the possible alternatives may be more 
informative or may have greater translational value than others.  
For example, family physicians have a clinical practice guideline for promoting smoking 
cessation [68], but their adherence to it is inconsistent. An RCT comparing family medical 
practice with versus without an adjunctive behavioral intervention could be designed either with 
a usual care or with a standard-of-care comparator. Usual care would reflect the inconsistent 
approach to smoking cessation counseling that is typically found in family practice settings and 
would thus be a clinically relevant comparator. A standard-of-care comparator, in contrast, 
would require all participating physicians to adhere to the clinical practice guidelines. It would 
be more uniform than usual care, and probably more formidable, but it would also be less 
relevant to typical family medical practice.  
How or why the intervention works: “How” or “why” questions often concern the extent to 
which the effects of complex interventions may be explained by certain components or by 
underlying mechanisms that these components purportedly target, rather than by other 
components or mechanisms. The most common variant concerns whether the components that 
are purportedly the unique, target-specific, or otherwise distinctive “active” ingredients of an 
intervention have effects on outcomes of interest that cannot be explained by nonspecific 
features such as attention. 
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Resemblance is one of the most important attributes of comparators that are used to test this 
kind of hypothesis, but it is difficult if not impossible to construct high-resemblance comparators 
for most complex behavioral interventions. Consequently, investigators often settle for ones that 
resemble the experimental intervention in some respects (e.g., the number of planned contacts) 
but not in others (e.g., the content of the sessions). For example, a multicenter RCT was 
conducted to determine whether the effects of maintenance CBT for recurrent depression 
“…might at least partially be explained by nonspecific factors”[69]. Manualized 
psychoeducation was used to represent these nonspecific factors. However, there were multiple 
differences in the content, format, and delivery of CBT and psychoeducation. Thus, the 
comparator did not literally consist of the nonspecific ingredients of CBT minus the special, 
distinctive, or target-specific ingredients of CBT. As is usually the case in this kind of trial, the 
“nonspecific” comparator was actually a different intervention, not a condition consisting 
entirely of the nonspecific components of the experimental intervention. 
There were two other differences between the groups, one planned and the other unplanned. 
Both interventions included 16 sessions over 8 months, but the psychoeducation sessions were 
30 minutes shorter than the CBT sessions. Only 73% of the participants completed at least 12 
sessions of psychoeducation, whereas 87% completed at least 12 sessions of CBT. This reflects 
another common drawback of attention-placebo and other common-factors comparators in 
behavioral trials: they tend to be less credible and engaging than the interventions to which they 
are compared. Consequently, they are vulnerable to differential adherence and attrition. 
Comparators such as psychoeducation that are used to address “why” questions are usually 
low in relevance. They are often artificial conditions that are constructed for RCTs rather than 
ones that are based on real-world, evidence-based practices. On the other hand, they tend to be 
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more formidable than wait lists, no-treatment groups, or usual care comparators in which many 
participants may receive no, minimal, or inadequate treatment. This helps to explain why they 
have also been used to address questions about “how well” interventions work. Unfortunately, 
their low relevance makes these comparators poor choices for such applications. In general, 
clinical trials have greater translational value when they compare health-related behavioral 
interventions to practice-relevant alternatives instead of to irrelevant ones. 
Because of the pervasive problem of low resemblance, typical artificial comparators may 
also be poor choices for trials that ask “how” or “why” questions about the active ingredients or 
underlying mechanisms of complex interventions. If a suitable high-resemblance comparator 
does not exist and cannot be created, it may not be feasible to parse the specific and nonspecific 
ingredients of the intervention. This may appear to leave the investigator at a dead end, but it can 
be taken instead as an opportunity to pursue one of several different research strategies.  First, it 
may be possible to turn the intervention itself into a comparator and to work towards developing 
a refined or novel intervention that can outperform it. This would pivot the research program 
from questioning the merits of an existing intervention to making progress towards the 
development of a more effective one. By repeating this approach over several cycles, a research 
program could produce a series of advances in treatment efficacy. In the long run, it will not 
matter whether the original intervention offered nothing more than attention, placebo, or 
common-factors effects, because better, more effective interventions will have supplanted it.  
Second, interventions that are well grounded in the science of behavior change [27] and 
carefully developed within frameworks such as MOST, ORBIT, MRC, or the NIH Stage Model, 
have usually been thoroughly scrutinized and optimized by the time they are tested in efficacy 
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trials. Basing interventions on well-specified models and compelling empirical evidence can help 
to prevent questions about their specific components from being raised in late-phase RCTs. 
Third, one of the reasons why the ostensibly special, active, or target-specific ingredients of 
complex behavioral interventions are often questioned is the suspicion that it might be possible 
to achieve similar results with simpler, less burdensome, or less expensive interventions. 
Nonsignificant results from superiority trials with attention-placebo or common-factors 
comparators should not be interpreted to mean that the interventions are equivalent. A better 
approach would be to design a noninferiority trial comparing the intervention to another bona 
fide intervention, i.e., one that is simpler, less expensive, and/or more convenient, and that is also 
suitable for real-world utilization [66]. For example, noninferiority trials have compared 
telephone-delivered vs. in-person genetic counseling [70, 71].  
Another approach is to evaluate the cost-effectiveness of the intervention, compared to other 
alternatives [72, 73]. The MOST framework can also incorporate constraints on interventions 
such as cost and dosage limits [74]. These approaches can identify interventions whose costs are 
justifiable in relation to the health outcomes they produce. They are particularly relevant to 
technology-based interventions that are often developed not to be superior to in-person 
interventions but to deliver noninferior results at less cost and with greater reach and scalability.    
Mismatches and multiple comparators: Mismatches between comparators and study purposes 
often occur when investigators attempt to answer more than one of three these types of questions 
in the same trial, or when reviewers ask them to do so. Answering one question well is better 
than answering multiple questions poorly.  
When investigators want to answer more than one of these kinds questions in a single trial, or 
when reviewers ask them to do so, a common solution is to compare the intervention to two 
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different comparators (i.e., in a three-arm trial). This may seem like an efficient research strategy 
but it can cause more problems than it solves. For example, a proposal to evaluate whether a 
novel intervention is superior to usual care may be criticized for “failing to control for attention.”  
However, a three-arm trial could be problematic in several ways. First, it is hard to justify asking 
whether an intervention works better than a clinically relevant alternative such as usual care at 
the same time that one is asking whether it provides nothing more than attention or placebo 
effects. Second, it is more expensive and difficult to conduct a three-arm than a two-arm trial, 
and it exposes more participants to experimentation. Third, three-arm trials can produce many 
different patterns of between-group differences and/or lack of differences; some of these patterns 
can be difficult to interpret and are potentially misleading [75-77]. Thus, the decision to add a 
third arm (i.e., a second comparator arm) to an RCT is one that should be carefully considered. 
 
7.5 Addressing significant barriers 
When a barrier to the use of a particular comparator is encountered, the investigator’s first 
task is to determine whether it is surmountable. If a relatively minor modification can make the 
comparator acceptable or feasible while preserving the trial’s ability to answer the primary 
research question or test the primary hypothesis, then the modification should be made. If that is 
not possible, it may be necessary to choose a different comparator, if there are others that are 
compatible with the trial’s primary purpose. For example, if a no-treatment comparator would be 
unacceptable for equity or ethical reasons but a wait-list would be acceptable, the investigator 
should use a wait-list comparator as long as it is compatible with the primary research question. 
The investigator would also have to consider the feasibility of this solution. If the goal were 
to estimate a short-term effect, then a wait-list comparator might be feasible; if the goal were 
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instead to estimate a long-term effect, then a wait-list might not be feasible. Resource constraints 
can also create barriers to the use of certain kinds of comparators, particularly for early-phase 
trials with small budgets. The investigator might have sufficient funds to provide the intervention 
to the experimental group but not enough to provide it to the comparison group. Consequently, a 
no-treatment comparator would be financially feasible, but a wait-list comparator would be 
infeasible. Thus, the investigator would be caught between the unacceptability of “no treatment” 
and the unaffordability of a wait-list comparator. In this circumstance, the impracticality of 
answering the original research question could become part of the rationale for pursuing a 
different yet still timely and important question. 
 
7.6 Addressing significant limitations 
It is often impossible to design comparators that have a perfect combination of attributes. 
Consequently, comparator-related limitations are unavoidable in many trials. When this occurs, 
the investigator may have to make some tradeoffs or compromises among comparator attributes. 
 Comparator choices can give rise to two different classes of limitations, structural and 
conditional. Structural limitations are built into the trial and can usually be recognized at the 
design or proposal stage. For example, a differential dosage of contact or attention between 
groups is a certainty when the experimental arm receives a behavioral intervention and the 
comparison group receives no treatment. In contrast, conditional limitations are not preordained, 
and they may or may not occur. For example, unanticipated differential attrition might occur in 
an RCT because the participants happen prefer one condition over the other. Conditional 
limitations are often associated with post-randomization biases or confounds, such as differential 
expectancies, differential attrition, or co-intervention biases. 
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 Structural limitations can be taken into account in the comparator selection process, but 
conditional limitations can only be taken into account if they are foreseeable. For example, 
prevention of differential attrition is one of the reasons why an investigator might choose an 
attention-placebo comparator, but differential attrition might occur anyway. This is not to say 
that conditional limitations should be ignored when trials are being designed, proposed, or 
reviewed. Foreseeable limitations should be carefully elucidated, especially ones that could 
seriously jeopardize the validity of the trial’s primary results. 
 It may also be helpful to consider whether an apparent limitation “is a feature, not a bug.” 
Differential attention, for example, could be problematic in a dismantling trial [65], but it is 
inseparable from the primary research question in eHealth and mHealth trials in which an app is 
augmented with counselor support in one group but not in the other [78]. It is also an essential 
feature of the trial if the research question is whether the outcome of an intervention is superior 
to that of existing practices, services, or treatments that provide less (or more) attention [6]. 
 The comparator’s limitations should be judged in relation to whether they would leave the 
primary research question unanswered. Less serious limitations rarely constitute sufficient 
grounds to reject a comparator that is well suited to the primary research question or hypothesis, 
particularly if they cannot be eliminated and there are no better alternatives. In some cases, 
concerns about the limitations of a comparator are misplaced proxies for concerns about the 
primary research question or hypothesis. The Pragmatic Model for Comparator Selection 
suggests that in this circumstance, it is more productive to question the primary purpose of the 
trial than to criticize the comparator.  
Also, many secondary questions can be addressed before an intervention is tested in a 
randomized controlled trial. However, trials are often conducted at times when a variety of 
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secondary questions remain to be addressed. If the limitations of a comparator leave important 
but secondary questions about an intervention unanswered, the model suggests that preventing 
the primary question from being answered is not the best solution. The unanswered questions of 
one trial may become the primary questions of future trials. This kind of programmatic research 
can, over time, overcome many of the limitations of individual trials.  
 
7.7 Finalizing the choice of the comparator 
The Pragmatic Model for Comparator Selection yields a comparator that addresses the 
primary research question, has no insurmountable barriers to its implementation, and no 
limitations that outweigh its compatibility with the primary research question or hypothesis. 
Investigators should document their decision process, so that readers understand why the 
comparator was selected and why other potential comparators were rejected. 
 
8. Summary and Conclusions 
Comparators are the lightning rods of health-related behavioral intervention research; they 
attract thunderbolts of controversy while diverting us from scrutinizing the purposes and goals of 
our trials. The Pragmatic Model for Comparator Selection in Health-Related Behavioral Trials 
provides a way to resolve many of the disagreements and controversies that surround the 
comparators that are used in behavioral intervention trials. It gives greater weight to the 
compatibility of the comparator with the primary research question or hypothesis than it does to 
the limitations of the comparator. It stresses the importance of carefully defining the primary 
research question or hypothesis, and of positioning and justifying every RCT within an 
applicable translational research framework.  It also recognizes that there may be barriers to the 
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use of otherwise optimal comparators, and it provides a pathway a pathway to follow when such 
barriers are encountered. The developers of this model hope that its adoption will help 
investigators, reviewers, oversight boards, and other stakeholders to address comparator-related 
disagreements and controversies that could impede progress in health-related behavioral 
intervention research if left unresolved.  
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